Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

Inclusion Criteria:

Patients with plasma cell myeloma treated with any number of prior lines of therapy, who at the time of study enrollment have had sustained MRD-negativity at a given timepoint and a subsequent time point with an interval of 3 or more years while on continuous maintenance therapy. MRD-negativity is defined per the International Myeloma Working Group Consensus Panel.
MRD positivity will be defined by detection of 1 or more neoplastic plasma cells in 10^5 nucleated cells by flow cytometry as per IMWG criteria (i.e., sensitivity of 10-5)
Age >/= 18 years with ECOG performance status Patients must be able to understand and be willing to sign a voluntary informed consent form and agree to compliance with the protocol schedule; with the knowledge that they may withdraw consent at any time without impact on future medical care

Exclusion Criteria:

Patients found to be MRD-positive at time of screening
Patients with plasma cell leukemia or other disorder of plasma cell neoplasm
Patient who are receiving other therapy with the intent of treating myeloma with the exception of bisphosphonates
Patients being treated for another, potentially life-limiting malignancy with 3-year lead-in to study enrollment, with the exception of non-melanoma skin cancer or in situ malignancy
Prior organ transplant or condition requiring immunosuppressive therapy
Prior allogeneic hematopoietic cell transplant
Patients with any other ongoing, concomitant, comorbid illness including but not limited to uncontrolled diabetes, NYHA class III or IV heart failure, uncontrolled coronary artery disease/arrhythmia, psychiatric or social disorder that would compromise compliance with the study schema